Articles by Miriam Monge - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Miriam Monge

Evaluating Disposable Mixing Systems

Drug manufacturers should follow a risk-assessment methodology when selecting a single-use mixing system for product development.
Feb 1, 2009

How to choose a disposable mixing system that fits your particular needs.

Disposable Technologies Implementation: Understanding and Managing Risks

In new disposables projects, it is critical that engineering, procurement, and operations groups work together early on to manage supply chain risk.
Dec 1, 2008

In new disposables projects, it is critical that engineering, procurement, and operations groups work together early on to manage supply chain risk.

The Environmental Impact of Disposable Technologies

Can disposables reduce your facility's environmental footprint?
Nov 2, 2008

Can disposables reduce your facility's environmental footprint? We have compared the environmental footprint of a traditional biopharmaceutical manufacturing facility using fixed-in-place stainless steel equipment, and a facility implementing disposable technologies for cell culture, solution mixing and hold, product hold, and liquid transfer.

Disposables Open Up Possibilities in Facility Design

When a new plant relies heavily on single-use technologies, facility design no longer depends on the process. Instead, other considerations, such as workflows, take center stage.
Aug 1, 2008

In addition to making technical developments, vendors are also looking at ways to improve supply-chain security. By offering standard, off-the-shelf products, vendors are able to shorten lead times and improve the security of supply.

Successful Project Management for Implementing Single-Use Bioprocessing Systems

Nov 2, 2006

In its early days, the biotech industry was almost entirely science driven, but it has since expanded from a laboratory environment to a sophisticated and dynamic manufacturing environment. As technological discoveries are increasingly translated into commercial products, biotech companies are realizing that they must generate a stronger return on assets.

ADVERTISEMENT

ADVERTISEMENT

Click here